Allogene Therapeutics Inc. (ALLO), a clinical-stage biotechnology company, on Monday, announced a proposed underwritten public offering of $175 million in shares of the company's common stock.
The proceeds from the public offering are expected to be used for general corporate purposes, clinical trial expenses, research and development, general and administrative expenses, and capital expenditure.
The company is currently developing allogenic CAR-T (Allo CAR T) therapies to treat autoimmune and cancer indications, including lymphoma, small cell lung cancer (SCLC), gastric and pancreatic cancers.
Additionally, Allogene is offering underwriters a 30-day option to purchase up to $26.25 million in shares.
ALLO closed Monday at $3.06, up 12.50%. In the overnight trade, shares were at $2.93, down 4.25%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.